In the present study in eyes with ongoing chronic anti-VEGF treatment for wet AMD, we found that visual function was stable during the observation period both in eyes subjected to switch of anti-VEGF agent from ranibizumab to aflibercept as well as in eyes on continued ranibizumab treatment. This evidence concerns the gene VEGFA and wet macular degeneration.